Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Phase 3 Trial of Decitabine Versus Patient's Choice (Supportive Care or Low-dose Cytarabine) in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
2005-004503-11Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of decitabine in acute myeloid leukemia (AML) (3 arms), sponsored by Eisai Co., Ltd. Primary endpoint: overall survival. Started Mar 2006; status: completed.
02
Drugs
decitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2005-004503-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004503-11.